Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for RIFAXIMIN
- Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
- Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia
- Pentoxifylline Plus Carvedilol vs Carvedilol Monotherapy in Preventing New Decompensation in Stable Cirrhotic Patients With Prior Decompensation
- To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea
- Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis
- The Efficacy and Safety of Rifaximin Treatment
- Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF)
- Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct
- Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients
- Effects of Rifaximin on Gut Microbiota and Emotion
- FMT for Post-infectious IBS
- A Randomized Single-Blind Controlled Trial Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation
- Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis
- Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
- Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients
- Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
- Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
- Effect of Probiotic (VSL#3) on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers
- Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
- Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.
- Rifaximin Therapy vs Low FODMAP Diet In IBS
- Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy
- Primary Prophylaxis for Spontaneous Bacterial Peritonitis
- Microbial Resistance of Rifaximin in Hepatic Encephalopathy
- Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease
- Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet
- Efficacy and Safety of Rifaximin With NAC in IBS-D
- Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy Volunteers
- Effect of a Probiotic Formula on Reducing SIBO in IBS Patients
- Multi-dimensional Clinical and Pathophysiological Profiles of Patients With Functional Dyspepsia and Effect of Gut Microbiota Manipulation Using Rifaximin for Its Treatment
- Rifaximin in Patients With Diabetic Gastroparesis
- Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
- Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
- Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
- Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis
- Autologous Transplant Targeted Against Crohn's
- Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial
- Rifamycin in Minimal Hepatic Encephalopathy
- Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D
- Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
- Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis
- PEG3350 in ACLF With Hepatic Encephalopathy
- Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin Users
- Modulation of Gut Microbiota by Rifaximin in PD Patients
- Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test
- Trial of Rifaximin in Probable Alzheimer's Disease
- Rifaximin in Patients With Monoclonal Gammopathy
- Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
- FMT in Cirrhosis and Hepatic Encephalopathy
- Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development
- Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes
- Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea
- Rifaximin to Modify the Disease Course in Sickle Cell Disease
- MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
- The Effect of Rifaximin on Portal Vein Thrombosis
- Fecal Microbiota Transplantation for Irritable Bowel Syndrome
- Microbiota Intervention to Change the Response of Parkinson's Disease
- Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome
- A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention
- Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation
- Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)
- Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.
- Rifaximin on Visceral Hypersensitivity
- A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
- Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's Disease
- Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's Disease
- Oral Fecal Transplant in Cirrhosis
- Simvastatin Plus Rifaximin in Decompensated Cirrhosis
- Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
- High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.
- Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites
- Rifaximin in Patients With Gastroesophageal Variceal Bleeding
- Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding
- A RCT COMPARING LACTULOSE AND RIFAXIMIN ASSOCIATED WITH A VEGETABLE DIET IN THE PREVENTION OF POST-TIPS OVERT HEPATIC ENCEPHALOPATHY
- A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.
- Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)
- Metabolic Consequences of Gastrointestinal Surgery
- Effect of Probiotics on Central Nervous System Functions in Humans
- Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease
- Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea
- GutHeart: Targeting Gut Microbiota to Treat Heart Failure
- Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease
- Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection
- Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices
- Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea
- Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD
- Rifaximin Use in Severe Alcoholic Hepatitis
- Treating Bacterial Overgrowth in Parkinson's Disease
- Fecal Microbiota Transplant for Inflammatory Bowel Disease
- Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial
- Fecal Microbiota Transplant (FMT) for Pouchitis
- Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis
- Rifaximin Therapy in Chronic Kidney Disease
- Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.
- Fecal Microbial Transplant in Pediatric Crohn's Disease
- One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
- One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
- Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial
- Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding
- Blood Lipopolysaccharide (LPS) Rifaximin Study
- Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
- Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis
- A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
- Rifaximin Predicts the Complications of Decompensated Cirrhosis
- Immunohistology in USDD and Correlation Between Bacterial Flora and Phlogosis
- Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS
- Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS
- Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients
- The Effects of Rifaximin Therapy in Irritable Bowel Syndrome
- Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients
- Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis
- The Rifaximin Study in CVID
- Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis
- Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients
- Rifaximin for Chronic Immune Activation in People With HIV
- The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
- Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
- The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
- Quality of Life and Nutritional Improvements in Cirrhotic Patients
- Evaluation of the Metabolome in Diverticular Disease
- Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement
- Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
- L-ornithine L-aspartate in Overt Hepatic Encephalopathy
- Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome
- Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea
- Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth
- Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease
- Rifaximin for Functional Dyspepsia
- Role of Methane in Glycemic Control
- Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea
- Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant
- Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
- A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans
- Rifaximin as a Modulator of Microbial Translocation and Immune Activation
- Rifaximin Treatment of Papulopustular Rosacea
- Rifaximin in Fatty Liver Disease
- Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer
- Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial
- Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease
- Study of Rifaximin in Minimal Hepatic Encephalopathy
- Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin
- Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)
- Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia
- Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex
- Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
- Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea
- Trial of Rifaximin in the Treatment of Tropical Enteropathy
- Rifaximin Versus Lactulose in Renal Failure
- Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers
- Rifaximin for Prevention of Travellers' Diarrhea
- Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
- Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
- Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy
- Gulf War Digestive Health Study
- Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?
- Induction of Clinical Response Using Rifaximin in Crohn's Disease
- Safety and Efficacy of AST-120 in the Treatment of Pouchitis
- Transit Time and Bacterial Overgrowth Using SmartPill Capsule
- Rifaximin in Minimal Hepatic Encephalopathy
- Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease
- RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
- Antibiotics for the Treatment of Ulcerative Colitis
- Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
- A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy
- Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea
- The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
- Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
- A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
- Rifaximin for the Treatment of Irritable Bowel Syndrome
- Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea
Clinical trials list
click for details